The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio or its related term are showing as below:
XSWX:SANN'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.5 Max: 4.95
Current: 0.65
During the past 13 years, Santhera Pharmaceuticals Holding AG's highest Cyclically Adjusted PB Ratio was 4.95. The lowest was 0.11. And the median was 0.50.
XSWX:SANN's Cyclically Adjusted PB Ratio is ranked better than 71.57% of 700
companies
in the Biotechnology industry
Industry Median: 1.64
vs XSWX:SANN: 0.65
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Santhera Pharmaceuticals Holding AG's adjusted book value per share data of for the fiscal year that ended in Dec25 was CHF-0.882. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF22.71 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Santhera Pharmaceuticals Holding AG (XSWX:SANN) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Santhera Pharmaceuticals Holding AG Cyclically Adjusted PB Ratio Related Terms
Santhera Pharmaceuticals Holding AG Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Cyclically Adjusted PB Ratio Chart
XSWX:SANN vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio falls into.
Santhera Pharmaceuticals Holding AG Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.65 mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Cyclically Adjusted PB Ratio of 0.65 as of Jul. 05, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. This is 30% above median its historical median of 0.50. Over the past decade, Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio has ranged from 0.11 to 4.95. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #199 out of 700 companies in the Biotechnology industry, placing it in the top 28.4%.
Is Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio too high?
Santhera Pharmaceuticals Holding AG's current Cyclically Adjusted PB Ratio of 0.65 is 30% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 4.95. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.64. Santhera Pharmaceuticals Holding AG's value of 0.65 is 60.4% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #199 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #199 out of 700 companies for Cyclically Adjusted PB Ratio. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.64. Santhera Pharmaceuticals Holding AG's value of 0.65 is 60.4% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Cyclically Adjusted PB Ratio has ranged from 0.11 to 4.95 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 1.64, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.64, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Cyclically Adjusted PB Ratio of 0.65 is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Cyclically Adjusted PB Ratio is 0.65, which is 30% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.25, compared to a current price of CHF14.80 — trading 36.3% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.65, which is 30% above median its 10-year median of 0.50 and 60.4% below the Biotechnology industry median of 1.64. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Cyclically Adjusted PB Ratio is 0.65 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF14.80 is trading 36.3% below its estimated GF Value™ of CHF23.25.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
Cyclically Adjusted PB Ratio: 0.65 (30% above median its 10-year median of 0.50)
GF Value™: CHF23.25 vs. price of CHF14.80 (36.3% below fair value)
Industry Position: 60.4% below the Biotechnology median (#199 of 700)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
